RT Journal Article
T1 Salivary DNA Methylation as an Epigenetic Biomarker for Head and Neck Cancer. Part I: A Diagnostic Accuracy Meta-Analysis
A1 Rapado González, Óscar
A1 Martínez Reglero, Cristina
A1 Salgado Barreiro, Ángel
A1 Muinelo Romay, Laura
A1 López López, Rafael
A1 Muinelo Lorenzo, Juan
A1 Díaz Lagares, Ángel
A1 Suárez Cunqueiro, María Mercedes
K1 DNA methylation
K1 Epigenetics
K1 Head and neck cancer
K1 Saliva
K1 Biomarkers
K1 Liquid biopsy
K1 Meta-analysis
AB DNA hypermethylation is an important epigenetic mechanism for gene expression inactivation in head and neck cancer (HNC). Saliva has emerged as a novel liquid biopsy representing a potential source of biomarkers. We performed a comprehensive meta-analysis to evaluate the overall diagnostic accuracy of salivary DNA methylation for detecting HNC. PubMed EMBASE, Web of Science, LILACS, and the Cochrane Library were searched. Study quality was assessed by the Quality Assessment for Studies of Diagnostic Accuracy-2, and sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (dOR), and their corresponding 95% confidence intervals (CIs) were calculated using a bivariate random-effect meta-analysis model. Meta-regression and subgroup analyses were performed to assess heterogeneity. Eighty-four study units from 18 articles with 8368 subjects were included. The pooled sensitivity and specificity of salivary DNA methylation were 0.39 and 0.87, respectively, while PLR and NLR were 3.68 and 0.63, respectively. The overall area under the curve (AUC) was 0.81 and the dOR was 8.34. The combination of methylated genes showed higher diagnostic accuracy (AUC, 0.92 and dOR, 36.97) than individual gene analysis (AUC, 0.77 and dOR, 6.02). These findings provide evidence regarding the potential clinical application of salivary DNA methylation for HNC diagnosis
PB MDPI
YR 2021
FD 2021
LK http://hdl.handle.net/10347/26711
UL http://hdl.handle.net/10347/26711
LA eng
NO J. Pers. Med. 2021, 11(6), 568; https://doi.org/10.3390/jpm11060568
NO This work was co-funded by the Instituto de Salud Carlos III (ISCIII) (PI20/01449) and the European Regional Development Fund (FEDER). A.D.-L. is funded by a “Juan Rodés” contract from ISCIII (JR17/00016). L.M.-R. is funded by a “Miguel Servet” contract from ISCIII (CP20/00129)
DS Minerva
RD 23 abr 2026